Syngene reports Q1 FY26 revenue higher at Rs. 875 Cr
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
Subscribe To Our Newsletter & Stay Updated